Omeprazole
Brand names: Losec, Prilosec
Omeprazole is a proton pump inhibitor used for gastro-oesophageal reflux disease, peptic ulcer disease, eradication regimens for Helicobacter pylori and the prevention of NSAID-associated ulcers.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It irreversibly inhibits the H+/K+-ATPase (proton pump) on the luminal surface of gastric parietal cells, markedly reducing both basal and stimulated gastric acid secretion.
Prescribing in practice
- Long-term or high-dose use is associated with hypomagnesaemia, an increased risk of fractures and a small increased risk of Clostridioides difficile and other enteric infections; review the indication periodically and use the lowest effective dose.
- It is a CYP2C19 inhibitor and can raise levels of interacting drugs; co-prescription with clopidogrel may reduce clopidogrel's antiplatelet effect.
- Acid suppression can mask the symptoms of gastric malignancy, so investigate alarm features before and during treatment.
Monitoring
Check serum magnesium before and periodically during prolonged therapy, and review the ongoing need for treatment at regular intervals.
Counselling the patient
- Take before food, typically in the morning, and swallow capsules whole.
- Report new diarrhoea, muscle cramps or unexplained tiredness, which may indicate infection or low magnesium.
- Do not stop abruptly after long-term use without discussing a step-down with your prescriber.
Evidence & guidelines
Proton pump inhibitor efficacy in acid-related disease is well established and reflected in NICE dyspepsia and GORD guidance.
Reference: NICE CG184 GORD; NICE NG12 H. pylori; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021